Smurfit WestRock (NYSE:SW) Azioni

Smurfit WestRock

Smurfit WestRock manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. After the merger of Smurfit Kappa and WestRock in summer 2024, Smurfit WestRock became the largest producer of containerboard in the world, with substantial operations in North America, South America, and Europe.

Smurfit WestRock PLC

SRISAWAD CRP PCL FRGN SHS by Srisawad Corp Pub Co Ltd.

Stran & Co Inc

Amplify ETF Trust Amplify BlackSwan Growth & Treasury Core ETF

TrustSwap

Swash

SHOCKWAVE MED INC

Smith & Wesson Brands, Inc. - Common Stock

Smith & Wesson Brands Inc

SOUTHWEST CASINO CORP by Southwest Casino Corp.

Southwest Casino Corp

SUNWAY CONSTR GRP by SUNWAY CONSTR GROUP BHD

SWCC Corp

SOFTWARE AG by Software AG

Swedbank AB

Swedencare AB

SKYWORTH GROUP LTD by Skyworth Group Limited

Skyworth Group Ltd

SKYWORTH GRP LTD UNSP/ADR by Skyworth Group Limited

SWEAT - United States Dollar

SWEEGEN INC by SweeGen, Inc.

Swell - United States Dollar

Swell Ethereum - United States Dollar

SwiftCoin - United States Dollar

SWATCH GROUP AG NEW ORD by Swatch Group AG

The Swatch Group AG

SWATCH GROUP AG UNSP/ADR by Swatch Group AG

SAWAI GROUP HLDGS CO LTD by SAWAI GROUP HLDGS CO LTD.

Sawai Group Holdings Co Ltd

STAR WEALTH GROUP INC by Star Wealth Group Inc.

SUMITOMO WAREHOUSE CO by Sumitomo Warehouse Co. Ltd.

Sumitomo Warehouse Co Ltd

SolarWinds Corp

Latham Group Inc

Solowin Holdings - Class A Ordinary Share

Solowin Holdings Ltd

Swingby

Southwest Iowa Renewable Energy LLC Units Series -A-

Southwest Iowa Renewable Energy LLC

SEKUR PRIVATE DATA LTD by SEKUR PRIVATE DATA LTD.

Sekur Private Data Ltd

Stanley Black & Decker, Inc. Common Stock

Stanley Black & Decker Inc

SWK Holdings Corp

SWK Holdings Corporation - 9.00% Senior Notes due 2027

Skyworks Solutions Inc

SILVER WOLF EXPLORATION by Silver Wolf Exploration Ltd.

Silver Wolf Exploration Ltd

Swedish Match AB ADR

STARWIN MEDIA HLDGS INC by Starwin Media Holdings, Inc.

Starwin Media Holdings Inc

Swarmio Media Holdings Inc

Southwestern Energy Company COM

Miratap Inc

EDM Resources Inc

SWSTRN MEDICAL SLTNS INC by Southwestern Medical Solutions, Inc.

Southwestern Medical Solutions Inc

SWEDISH ORPHAN BIO U/ADR by Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB

SOFTWAREONE HLDG AG by SOFTWAREONE HLDG AG

SoftwareONE Holding AG

Swop

SWP Growth & Income ETF

Kava Swap

SWIRE PROPERTIES LTD ORD by Swire Properties Ltd.

Swire Properties Ltd

SWIRE PROPERTIS UNSP/ADR by Swire Properties Ltd.

SWISS PRIME SITE AG U/ADR by Swiss Prime Site AG

Swiss Prime Site AG

SWOOP HOLDINGS LTD by Swoop Holdings Ltd.

Swoop Holdings Ltd

SWISS PRIME SITE AG by Swiss Prime Site AG

SHOWA PAXXS CORP TOKYO by SHOWA PAXXS CORP

SWISSQUOTE GROUP HOLDING by Swissquote Group Holding AG

Swissquote Group Holding SA

SWIRE PACIFIC LTD A by Swire Pacific Ltd.

Swire Pacific Ltd

SWIRE PAC LTD A S/ADR by Swire Pacific Ltd.

SWIRE PACIFIC LTD B ORD by Swire Pacific Ltd.

SWIRE PACIFIC LTD B S/ADR by Swire Pacific Ltd.

SHIBUSAW LOGISTICS CORP by SHIBUSAW LOGISTICS CORP

Shibusawa Logistics Corp

SEAWRIGHT HOLDINGS INC by Seawright Holdings, Inc.

Seawright Holdings Inc

U-Swirl Inc

AppSwarm Inc

Swerve

SWISS LIFE HOLDING AG by Swiss Life Holding

Swiss Life Holding AG

CLEAN ENGY SPCL SITUTINS by Clean Energy Special Situations Corp.

Clean Energy Special Situations Corp

SWISS WTR DECAF COFFEE by Swiss Wtr Decaffinated Coffee Inc.

Swiss Water Decaffeinated Coffee Inc

Clean Energy Special Situations Corp Units (1 Ord & 1/2 War)

Clean Energy Special Situations Corp Warrants (01/12/2027)

Carbon

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics Inc

Swvl Holdings Corp

SIMON WORLDWIDE INC by Simon Worldwide, Inc.

Simon Worldwide Inc

Southwest Gas Holdings, Inc. Common Stock (DE)

Southwest Gas Holdings Inc

Sanoma Oyj

STORNOWAY DIAMOND CORP by Stornoway Diamond Corp.

Stornoway Diamond Corp

Total Return Securities Fund Common Stock

Swiss Helvetia Fund Inc

Swisscom AG

SCHWEIZERISCHE NATLBANK by Schweizerische Nationalbank

Schweizerische Nationalbank

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) with a Buy and maintains $4 price target.

News

Price Target

Reiteration

Analyst Ratings

PHIO

HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $4 Price Target

The most oversold stocks in the energy sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Noble Corporation PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>)</h3>
<ul>
<li>On April 7, Barclays analyst Eddie Kim maintained Noble Corp with an Overweight rating and lowered the price target from $39 to $29. The company's stock fell around 19% over the past five days and has a <a href="https://www.benzinga.com/quote/NE">52-week low of $17.40</a>.</li>
<li>RSI Value: 29.2</li>
<li>NE Price Action: Shares of Noble gained 5.4% to close at $19.41 on Monday.</li>
<li>Edge Stock Ratings: 8.25 Momentum score with Value at 93.03. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/ne"><img loading="lazy" decoding="async" width="412" height="171" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08030815/image-28.png" alt="" class="wp-image-861266" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08030815/image-28.png 412w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08030815/image-28-300x125.png 300w" sizes="(max-width: 412px) 100vw, 412px" /></a></figure>
<h3 class="wp-block-heading">Seadrill Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>)</h3>
<ul>
<li>On March 19, Citigroup analyst Scott Gruber maintained Seadrill with a Buy rating and lowered the price target from $46 to $35. The company's stock fell around 20% over the past month and <a href="https://www.benzinga.com/quote/SDRL">has a 52-week low</a> of $18.25.</li>
<li>RSI Value: 27.3</li>
<li>SDRL Price Action: Shares of Seadrill gained 4.4% to close at $20.08 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408">SDRL stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="930" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08030900/image-29.png" alt="" class="wp-image-861268" style="width:534px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08030900/image-29.png 930w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08030900/image-29-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08030900/image-29-768x691.png 768w" sizes="(max-width: 930px) 100vw, 930px" /></figure>
<h3 class="wp-block-heading">Nabors Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBR#NYSE">NBR</a>)</h3>
<ul>
<li>On March 27, Morgan Stanley analyst Daniel Kutz maintained Nabors Industries with an Overweight rating and lowered the price target from $115 to $75. The company's stock fell around 28% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/NBR">low of $26.23.</a></li>
<li>RSI Value: 25.8</li>
<li>NBR Price Action: Shares of Nabors Industries gained 3.1% to close at $29.86 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408">NBR shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408"><img loading="lazy" decoding="async" width="867" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08031003/image-30.png" alt="" class="wp-image-861269" style="width:491px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08031003/image-30.png 867w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08031003/image-30-300x288.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08031003/image-30-768x736.png 768w" sizes="(max-width: 867px) 100vw, 867px" /></a></figure>
BZ Edge Rankings: Find out where other stocks stand—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">explore the full comparison now</a>.
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44669062/top-3-health-care-stocks-that-may-crash-in-q2">Top 3 Health Care Stocks That May Crash In Q2</a> </li>
<li></li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

SDRL

Top 3 Energy Stocks You'll Regret Missing In Q2

JP Morgan analyst Bryan Smilek downgrades Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) from Neutral to Underweight.

Downgrades

CHGG

JP Morgan Downgrades Chegg to Underweight

Contracts

V2X Awarded $62M Contract To Support COBRA DANE Radar Operational Readiness Through 2027

General

KIDZ

KIDZW

Classover Announces Development Of A Next-Generation Artificial Intelligence Powered Tutoring Platform

JP Morgan analyst Matthew Boss upgrades Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) from Neutral to Overweight and lowers the price target from $19 to $17.

Upgrades

LEVI

JP Morgan Upgrades Levi Strauss to Overweight, Lowers Price Target to $17

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and maintains $133 price target.

BPMC

Needham Reiterates Buy on Blueprint Medicines, Maintains $133 Price Target

JP Morgan analyst Richard Shane upgrades Essent Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESNT#NYSE">ESNT</a>) from Neutral to Overweight and maintains the price target from $60 to $60.

ESNT

JP Morgan Upgrades Essent Group to Overweight, Maintains Price Target to $60

Management

Harley-Davidson's Board Of Directors Confirm On-Going CEO Search Process

As global markets continue to swing wildly in the aftermath of Trump's tariffs coming into play, an old observation from Berkshire Hathaway&#8217;s former vice-chair, <a href="https://www.benzinga.com/25/04/44659224/billionaire-charlie-munger-said-hed-be-the-richest-man-on-earth-if-he-could-go-back-100-years-and-start-over-i-could-have-done-a-lot-better">Charlie Munger,</a><a href="https://www.benzinga.com/25/04/44659224/billionaire-charlie-munger-said-hed-be-the-richest-man-on-earth-if-he-could-go-back-100-years-and-start-over-i-could-have-done-a-lot-better"> sounds more relevant than ever</a>. 
What Happened: During volatility, Munger once told shareholders: "The market is not going to do exactly what you want when you want it&#8230;&#8221;
&#8220;I wouldn&#8217;t worry too much about what happens over six months or twelve months. I don&#8217;t think you&#8217;re really all that welcome in this room if the short-term orientation is what turns you on."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Charlie Munger: &quot;The market is not going to do exactly what you want when you want it &#8230; I wouldn&#39;t worry too much about what happens over six months or twelve months. I don&#39;t think you&#39;re really all that welcome in this room if the short-term orientation is what turns you on.&quot; <a href="https://t.co/yQLY20cK4P">pic.twitter.com/yQLY20cK4P</a>
&mdash; Kevin Carpenter (@kejca) <a href="https://twitter.com/kejca/status/1908919285847556486?ref_src=twsrc%5Etfw">April 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/04/44680547/dave-ramsey-caller-asks-if-they-should-stop-contributing-during-market-collapse-ten-years-from-now-you-wont-even-remember-this-crap">Dave Ramsey Caller Asks If They Should Stop Contributing During Market Collapse — &#8216;Ten Years From Now You Won&#8217;t Even Remember This Crap&#8217;</a>
Why It Matters: Trump's sweeping tariffs have triggered a <a href="https://www.benzinga.com/general/market-summary/25/04/44679853/wall-street-eyes-recovery-as-sp-500-nasdaq-futures-rise-after-trumps-tariff-driven-selloff-wipes-out-9-trillion-in-six-weeks">market meltdown, wiping out $9 trillion</a> in just six weeks—an impact rivaling the losses seen during the peak of the COVID-19 crash and surpassing the year-long decline following the 2008 Lehman Brothers collapse, according to Bear Traps Report founder Lawrence McDonald.
On Monday, stocks swung as investors responded to contradictory signals. Hopes that tariffs might be halted for a bit pushed the S&amp;P 500 almost 7% from its recent low, only for the market to change course when the Trump administration confirmed the 25% hike on Chinese goods would go ahead. <a href="https://www.benzinga.com/news/global/25/04/44679330/will-trump-impose-higher-tariffs-on-china-crypto-bettors-now-see-an-80-possibility">China threatened retaliation, leading to a fresh wave of uncertainty</a>. By evening, futures for the Dow, S&amp;P 500, and Nasdaq-100 had each climbed by more than 1%.

The recent episode underscores just how reactive markets have become—bouncing on speculation, then falling on confirmation. <a href="https://www.benzinga.com/markets/25/04/44657195/charlie-munger-slams-teaching-stock-trading-to-young-people-its-like-trying-to-induce-young-people-to-start-off-on-heroin">Munger's lesson highlights the danger of chasing headlines</a> and banking on instant gratification from markets that are, by nature, unpredictable.
At a time when even experienced investors are tempted to time the chaos, <a href="https://www.benzinga.com/personal-finance/25/04/44654791/billionaire-charlie-munger-hated-being-told-what-to-do-he-said-getting-rich-meant-you-could-say-to-hell-with-them-and-avoid-needing-anyone">Munger's reminder</a> stands steady: patience beats panic, particularly when the noise is loudest.
Image via Shutterstock
Read Next: <a href="https://www.benzinga.com/25/04/44681272/jim-cramer-questions-market-strength-amid-chinas-retaliatory-tariffs-oversold-panic-or-a-big-trap">Jim Cramer Cautions Against Jumping In As Oversold Market Sparks Futures Rebound Without Clear Catalyst: &#8216;Is It All A Big Trap?&#8217;</a>

Equities

Charlie Munger Once Said, 'The Market Won't Do Exactly What You Want, When You Want' — As Tariff Jitters And Wild Swings Remind Investors Why Long-Term Thinking Matters

JP Morgan analyst Richard Shane upgrades Guild Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHLD#NYSE">GHLD</a>) from Underweight to Neutral and lowers the price target from $12.5 to $12.

GHLD

JP Morgan Upgrades Guild Holdings to Neutral, Lowers Price Target to $12

Health Care

KURA

Kura Oncology Submits New Drug Application (NDA) To The FDA For ziftomenib For The Treatment Of Acute Myeloid Leukemia (AML)

JP Morgan analyst Jimmy Bhullar upgrades RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) from Neutral to Overweight and maintains the price target from $284 to $284.

JP Morgan Upgrades RenaissanceRe Holdings to Overweight, Maintains Price Target to $284

Biotech

Financing

Offerings

IBRX

ImmunityBio Announced Registered Direct Offering Of Approximately $75M In Gross Proceeds With A Single Institutional Investor, If Fully Exercised, The Warrants Could Result In Additional Gross Proceeds Of Up To Approximately $90M

JP Morgan analyst Jimmy Bhullar upgrades Palomar Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLMR#NASDAQ">PLMR</a>) from Neutral to Overweight and raises the price target from $115 to $150.

PLMR

JP Morgan Upgrades Palomar Hldgs to Overweight, Raises Price Target to $150

ZENA

ZenaTech Scales Domestic Drone Production For Commercial And Defense Markets Without Raising Prices

Dividends

SIGA

SIGA Technologies Declared A Special Cash Dividend Of $0.60 Per Share Payable On May 15, 2025, To Shareholders Of Record At The Close Of Business On April 29, 2025

GXAI

Gaxos.ai Launches AI-Enabled Gaxos Health Mobile Application For iOS And Android

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) with a Buy and maintains $23 price target.

LXEO

HC Wainwright & Co. Reiterates Buy on Lexeo Therapeutics, Maintains $23 Price Target

<ul>
<li>Since providing initial guidance, the Company received larger than expected orders during the final week of March, and has also obtained additional visibility into inventory levels on hand at some of our current purchasing customers. Based on this new information, CorMedix is increasing its H1 2025 guidance for Net Sales to existing purchasing customers to a revised range of $62 million to $70 million.</li>
<li>While the Company is currently forecasting net sales from existing purchasing customers in 2Q 2025 to be lower than 1Q 2025, this is due to the timing of shipments to those customers between quarters, and does not suggest an anticipated decrease in patient utilization in the second quarter or the second half of 2025. CorMedix currently forecasts patient utilization with existing purchasing customers to continue to grow throughout 2025 as implementation expands to new patients, and currently anticipates unit shipments in H2 2025 to exceed shipments in H1 2025.</li>
<li>CorMedix expects patient enrollment for our Phase 3 study of DefenCath in patients receiving Total Parenteral Nutrition, or TPN, to begin in late April. The Company believes DefenCath, if approved for this indication, can achieve peak annual sales in this patient population of $150 million to $200 million, with a total addressable market opportunity of $500 million to $750 million.</li>
<li>Cash and short-term investments, excluding restricted cash, at March 31, 2025 amounted to approximately $77.5 million</li>
</ul>

Earnings

Guidance

CRMD

CorMedix Announces Preliminary Revenue Of $39M For 1Q 2025 Vs. Consensus Of $32.20M, And Expects 1Q 2025 Adjusted EBITDA (To Exceed $22.5M Once Final Numbers Are Reported)

Press Releases

Smurfit Westrock Announces that one of its subsidiaries, WRKCo Inc., Makes Application to Cease to be a Reporting Issuer in Certain Canadian Jurisdictions

Comments

Smurfit WestRock

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO